Tacrolimus Treatment for Refractory Autoimmune Cytopenia
Status:
Unknown status
Trial end date:
2021-11-10
Target enrollment:
Participant gender:
Summary
Autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA), pure red cell aplasia
(PRCA), Evans syndrome (ES), usually has good responses to steroids therapies as first line,
but there is a considerable percentage of patients who relapse, become refractory or
dependent on steroids to maintain an acceptable level of hemoglobin or platelets. The effects
of the second line therapy are also not satisfactory and sometimes not available. The
investigators aim to explore the efficacy and side-effect of tacrolimus for refractory
autoimmune cytopenia.